Summary
The report provides a complete review of Poland's pharmaceuticals market, including data for 2001-2004 and three-year market projections.
All statistics are presented both in value and volume, and are broken down by the following market segments:
- Rx, OTC and hospital;
- brand name and generic;
- domestically manufactured and imported.
Detailed data on 14 main ATC drug categories, in 90 sub-categories, is also included.
On top of in-depth analyses on the current condition of the domestic pharmaceutical sector (which considers employment, revenue, profit and profitability), the report sets out a comprehensive presentation of various aspects of the sector's operation in Poland, covering: drug distribution, research and development and the climate for innovation, foreign investment and clinical research. Moreover, details as to the legal environment, with a strong focus on drug registration, marketing authorisation and advertising of medicinal products in Poland are covered.
As an added feature to the pharmaceutical market study, the report presents the general structure, key figures and financing of the healthcare sector in Poland, together with specific analyses on the private medical segment.
The report is comprised of the following sections:
- Poland's economic performance;
- Analyses of pharmaceutical-related consumer spending;
- Legal environment of the market;
- Market size in value and volume;
- Sales of pharmaceuticals by therapeutic categories (ATC);
- Foreign trade of pharmaceuticals;
- Economic analysis of the Polish pharmaceutical sector;
- Top pharmaceutical companies on the market;
- Distribution of pharmaceuticals in Poland;
- Polish healthcare sector analysis.
The target audience of this report is
- top managers and strategic planners of pharmaceutical companies considering entering the Polish market;
- local pharmaceuticals manufacturers looking for accurate and reliable market intelligence;
- consulting agencies and legal advisors;
- commercial associations and governmental agencies;
- financial institutions (i.e. brokerage houses and investment banks);
- drug wholesalers and pharmacy owners;
- international pharmacy and retail chains interested in entering Polish drug distribution market.
|
